Ruyue Xu

430 total citations
19 papers, 297 citations indexed

About

Ruyue Xu is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Ruyue Xu has authored 19 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Ruyue Xu's work include Cancer Mechanisms and Therapy (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Ruyue Xu is often cited by papers focused on Cancer Mechanisms and Therapy (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Ruyue Xu collaborates with scholars based in China and United States. Ruyue Xu's co-authors include Amin Li, Yongfang Ma, Weiya Cao, Shuping Zhou, Yinci Zhang, Xinkuang Liu, Song Li, Xiaolong Tang, Xueke Liu and Shuyu Cai and has published in prestigious journals such as Frontiers in Microbiology, Ecotoxicology and Environmental Safety and BioMed Research International.

In The Last Decade

Ruyue Xu

19 papers receiving 295 citations

Peers

Countries citing papers authored by Ruyue Xu

Since Specialization

Citations

This map shows the geographic impact of Ruyue Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruyue Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruyue Xu more than expected).

Fields of papers citing papers by Ruyue Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruyue Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruyue Xu. The network helps show where Ruyue Xu may publish in the future.

Co-authorship network of co-authors of Ruyue Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Ruyue Xu. A scholar is included among the top collaborators of Ruyue Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruyue Xu. Ruyue Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	G protein-coupled receptor 107 deficiency promotes development of diabetic nephropathy 2025 ·Molecular Biomedicine ·Deping Xu, (unknown), Ping Yang, Qiong Chen, Suhua Wang, Wei Zhao, (unknown), Yu Yin, Ruyue Xu, Min Zhang, Chunlin Cai, Deguang Wang, Dandan Zang, (unknown), Haisheng Zhou	1
2	Effect of biopolymer chitosan on manganese immobilization improvement by microbial‑induced carbonate precipitation 2024 ·Ecotoxicology and Environmental Safety ·(unknown), Luming Shen, Ruyue Xu, Xue Dong, (unknown), Huajie Gu, Fenju Qin, Hengwei Liu	7
3	Heavy metal bioremediation using microbially induced carbonate precipitation: Key factors and enhancement strategies 2023 ·Frontiers in Microbiology ·Wenchao Zhang, Hong Zhang, Ruyue Xu, (unknown), (unknown), Kun Zhao	32
4	IL‐6 upregulates the expression of IL‐6R through the JAK2/STAT3 signalling pathway to promote progression of hepatocellular carcinoma 2023 ·Scandinavian Journal of Immunology ·(unknown), Ruyue Xu, (unknown), Jiaojiao Liang, (unknown), Jiafeng Gao, (unknown)	4
5	c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway 2022 ·Journal of Molecular Medicine ·Ruyue Xu, Xinkuang Liu, Amin Li, Song Li, Jiaojiao Liang, Jiafeng Gao, Xiaolong Tang	25
6	Nanoparticles Loaded with GSK1059615 Combined with Sorafenib Inhibited Programmed Cell Death 1 Ligand 1 Expression by Negatively Regulating the PI3K/Akt/NF-κB Pathway, Thereby Reversing the Drug Resistance of Hepatocellular Carcinoma to Sorafenib 2022 ·Journal of Biomedical Nanotechnology ·Shuping Zhou, Yongfang Ma, Ruyue Xu, (unknown)	9
7	BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy 2021 ·BioMed Research International ·Weiya Cao, Xueke Liu, (unknown), Amin Li, (unknown), Shuping Zhou, Song Li, Ruyue Xu, Yongfang Ma, (unknown), (unknown)	18
8	Curcumin reverses hepatic epithelial mesenchymal transition induced by trichloroethylene by inhibiting IL-6R/STAT3 2021 ·Toxicology Mechanisms and Methods ·Weiya Cao, Yinci Zhang, Amin Li, Pan Yu, Song Li, Jiaojiao Liang, (unknown), Jiafeng Gao, Ruyue Xu, Yongfang Ma, Xiaolong Tang	19
9	Development of chemiluminescence method based on serum type I collagen hydroxyl terminal peptide β special sequence (β-CTX) 2021 ·Scandinavian Journal of Clinical and Laboratory Investigation ·Zhen Huo, Xueke Liu, (unknown), Yong Liang, Ruyue Xu, Yongfang Ma, Song Li, Jing Shen, Xiaolong Tang	2
10	LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway 2021 ·Molecular Medicine Reports ·Ruyue Xu, Yinci Zhang, Amin Li, Yongfang Ma, (unknown), Song Li, (unknown), Shuping Zhou, Weiya Cao, (unknown)	22
11	LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells 2021 ·International Journal of Medical Sciences ·Yongfang Ma, Ruyue Xu, Xueke Liu, Yinci Zhang, Song Li, Shuyu Cai, Shuping Zhou, (unknown), Amin Li, Weiya Cao, (unknown)	28
12	Targeted Delivery of Glypican 3 (GPC3) Antibody-Modified MicroRNA (miR let-7b-5p) Polymer Nanoparticles to Sorafenib-Resistant Hepatsocellular Carcinoma Cells 2021 ·Journal of Biomedical Nanotechnology ·Shuping Zhou, Yongfang Ma, Xueke Liu, Pan Yu, Ning Huang, Song Li, Ruyue Xu, Zhen Huo, Tao Zhu, Xiaolong Tang	8
13	Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells 2020 ·Journal of Cancer Research and Clinical Oncology ·Amin Li, Weiya Cao, Xueke Liu, Yinci Zhang, Yongfang Ma, Ruyue Xu, Rongbo Zhang, Xinkuang Liu, Shuping Zhou, (unknown), Jiachang Liu, (unknown)	14
14	hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway 2020 ·Nanoscale Research Letters ·Jing Shen, (unknown), Yongfang Ma, Ruyue Xu, Zhen Huo, Song Li, (unknown), Yinci Zhang, Amin Li, Weiya Cao, Shuping Zhou, Xiaolong Tang	17
15	Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells 2020 ·Translational Cancer Research ·Amin Li, Weiya Cao, Xueke Liu, Yinci Zhang, Yongfang Ma, Ruyue Xu, (unknown)	1
16	Anti-GPC3 Antibody-Conjugated BEZ235 Loaded Polymeric Nanoparticles (Ab-BEZ235-NP) Enhances Radiosensitivity in Hepatocellular Carcinoma Cells by Inhibition of DNA Double-Strand Break Repair 2020 ·Journal of Biomedical Nanotechnology ·Yong Liang, Chunmei Xie, (unknown), Zhen Huo, (unknown), (unknown), Weiya Cao, Yongfang Ma, Ruyue Xu, Zhenyou Jiang, Dong Ma, (unknown)	5
17	PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway. 2019 ·PubMed ·Yinci Zhang, Chunmei Xie, Amin Li, Xueke Liu, (unknown), Jing Shen, Zhen Huo, Shuping Zhou, Xinkuang Liu, (unknown), Weiya Cao, Yongfang Ma, Ruyue Xu, (unknown), (unknown), Dong Ma	36
18	BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway. 2019 ·PubMed ·Amin Li, Rongbo Zhang, Yinci Zhang, Xueke Liu, (unknown), Jiachang Liu, Xinkuang Liu, (unknown), Weiya Cao, Ruyue Xu, Yongfang Ma, (unknown), (unknown), Shuyu Cai, (unknown)	29
19	BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway. 2019 ·PubMed ·Xueke Liu, Chunmei Xie, Amin Li, Yinci Zhang, Xinkuang Liu, Shuping Zhou, Jing Shen, Zhen Huo, Weiya Cao, Yongfang Ma, Ruyue Xu, (unknown), (unknown), Shuyu Cai, (unknown)	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact